We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-8.4%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$4.07B
AUM Growth
-$732M
(-15%)
Cap. Flow
-$324M
Cap. Flow
% of AUM
-7.96%
Top 10 Holdings %
Top 10 Hldgs %
18.03%
Holding
679
New
46
Increased
261
Reduced
260
Closed
64
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$31.9M |
| 2 |
McKesson
MCK
|
+$27.5M |
| 3 |
Procter & Gamble
PG
|
+$27.1M |
| 4 |
Starbucks
SBUX
|
+$27M |
| 5 |
NVIDIA
NVDA
|
+$21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$109M |
| 2 |
iShares US Real Estate ETF
IYR
|
+$31.3M |
| 3 |
EMC
EMC CORPORATION
EMC
|
+$24.7M |
| 4 |
SNI
Scripps Networks Interactive, Inc Common Class A
SNI
|
+$23.8M |
| 5 |
K
Kellanova
K
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.72% |
| 2 | Financials | 13.85% |
| 3 | Technology | 10.05% |
| 4 | Consumer Discretionary | 8.55% |
| 5 | Consumer Staples | 8.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Vanguard Large-Cap ETF
VV
$51.9B
| $3.94M | 0.1% |
44,775
-500
| -1% | -$46.7K |
|
|
CLVS
227
DELISTED
Clovis Oncology, Inc.
CLVS
| $3.94M | 0.1% |
42,800
-17,200
| -29% | -$1.49M |
|
228
Ionis Pharmaceuticals
IONS
$9.35B
| $3.87M | 0.1% |
95,685
+15,685
| +20% | +$812K |
|
229
Larimar Therapeutics
LRMR
$416M
| $3.85M | 0.09% |
10,033
+1,700
| +20% | +$766K |
|
230
Automatic Data Processing
ADP
$100B
| $3.8M | 0.09% |
47,338
-19,676
| -29% | -$1.58M |
|
231
Franklin Resources
BEN
$16.9B
| $3.79M | 0.09% |
101,719
-37,440
| -27% | -$1.62M |
|
|
BLUE
232
DELISTED
bluebird bio
BLUE
| $3.78M | 0.09% |
3,412
-834
| -20% | -$1.52M |
|
233
Molson Coors Class B
TAP
$7.68B
| $3.77M | 0.09% |
45,364
-139,024
| -75% | -$10.1M |
|
234
Goldman Sachs
GS
$313B
| $3.76M | 0.09% |
21,659
-184
| -0.8% | -$36.1K |
|
235
O'Reilly Automotive
ORLY
$72.4B
| $3.71M | 0.09% |
222,315
+155,295
| +232% | +$2.51M |
|
|
SWN
236
DELISTED
Southwestern Energy Company
SWN
| $3.69M | 0.09% |
291,130
-136,796
| -32% | -$2.38M |
|
|
GHDX
237
DELISTED
Genomic Health, Inc.
GHDX
| $3.69M | 0.09% |
174,400
-9,600
| -5% | -$247K |
|
|
MRTX
238
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $3.68M | 0.09% |
107,000
-3,000
| -3% | -$90.7K |
|
239
Kraft Heinz
KHC
$30.4B
| $3.63M | 0.09% |
+51,380
| New | +$3.88M |
|
|
KANG
240
DELISTED
iKang Healthcare Group, Inc.
KANG
| $3.63M | 0.09% |
245,000
-78,000
| -24% | -$1.26M |
|
241
Neurocrine Biosciences
NBIX
$17.7B
| $3.62M | 0.09% |
91,000
-14,000
| -13% | -$677K |
|
242
BCE
BCE
$19.9B
| $3.59M | 0.09% |
88,115
+7,638
| +9% | +$313K |
|
|
RHT
243
DELISTED
Red Hat Inc
RHT
| $3.54M | 0.09% |
49,264
+30,797
| +167% | +$2.32M |
|
244
Suncor Energy
SU
$77.7B
| $3.49M | 0.09% |
131,263
+4,740
| +4% | +$127K |
|
|
TSRO
245
DELISTED
TESARO, Inc.
TSRO
| $3.43M | 0.08% |
85,500
+8,500
| +11% | +$465K |
|
|
WRK
246
DELISTED
WestRock Company
WRK
| $3.4M | 0.08% |
+73,283
| New | +$3.93M |
|
247
Target
TGT
$62.1B
| $3.38M | 0.08% |
42,929
+1,509
| +4% | +$120K |
|
248
Devon Energy
DVN
$51.9B
| $3.34M | 0.08% |
89,985
+11,659
| +15% | +$535K |
|
|
SPLS
249
DELISTED
Staples Inc
SPLS
| $3.34M | 0.08% |
284,364
-158,320
| -36% | -$2.23M |
|
250
Teva Pharmaceuticals
TEVA
$35.9B
| $3.33M | 0.08% |
58,993
-43,730
| -43% | -$2.84M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2015 Portfolio in Review
As of Q3 2015, Candriam SCA held 679 positions worth $4.07B, down 15% from $4.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA withdrew a net $324M in Q3 2015, closing 64 positions and reducing 260 holdings. Its most notable exit was Alphabet (Google) Class C, an estimated $109M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 29% a quarter earlier, followed by Financials and Technology.
Against the trend, Candriam SCA opened a new position in Masco worth $14.9M.
- Candriam SCA's largest Q3 2015 buy was Masco: 593,671 shares worth $14.9M.
- Candriam SCA added most to Nike in Q3 2015, an estimated $31.9M increase.
- Candriam SCA's biggest Q3 2015 reduction was iShares US Real Estate ETF, cutting an estimated $31.3M.
- Candriam SCA fully exited Alphabet (Google) Class C in Q3 2015, selling an estimated $109M.
- Candriam SCA's ten largest holdings make up 18% of its $4.07B portfolio in Q3 2015.
- Candriam SCA opened 46 new positions and closed 64 in Q3 2015.
- Candriam SCA's portfolio value fell 15% quarter-over-quarter to $4.07B.
Based on Candriam SCA's 13F filing for Q3 2015, filed 19 Oct 2015.